142 related articles for article (PubMed ID: 21396362)
1. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models.
Krauss AH; Impagnatiello F; Toris CB; Gale DC; Prasanna G; Borghi V; Chiroli V; Chong WK; Carreiro ST; Ongini E
Exp Eye Res; 2011 Sep; 93(3):250-5. PubMed ID: 21396362
[TBL] [Abstract][Full Text] [Related]
2. A digoxin derivative that potently reduces intraocular pressure: efficacy and mechanism of action in different animal models.
Barathi VA; Katz A; Chaudhary S; Li HL; Tal DM; Marcovich A; Do CW; Karlish SJD
Am J Physiol Cell Physiol; 2024 May; 326(5):C1505-C1519. PubMed ID: 38557355
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Heat Shock Protein 90 Lowered Intraocular Pressure without Affecting the Production of Aqueous Humor in Rabbits.
Takahashi Y; Otsuka T; Arakawa R; Naito A
Ophthalmic Res; 2024; 67(1):23-28. PubMed ID: 38071969
[TBL] [Abstract][Full Text] [Related]
4. CRISPR-Cas9-mediated deletion of carbonic anhydrase 2 in the ciliary body to treat glaucoma.
Jiang J; Kong K; Fang X; Wang D; Zhang Y; Wang P; Yang Z; Zhang Y; Liu X; Aung T; Li F; Yu-Wai-Man P; Zhang X
Cell Rep Med; 2024 May; 5(5):101524. PubMed ID: 38670096
[TBL] [Abstract][Full Text] [Related]
5. Enhancing the hypotensive effect of latanoprost by combining synthetic phosphatidylcholine liposomes with hyaluronic acid and osmoprotective agents.
Brugnera M; Vicario-de-la-Torre M; González-Cela Casamayor MA; López-Cano JJ; Bravo-Osuna I; Huete-Toral F; González Rubio ML; Carracedo G; Molina-Martínez IT; Andrés-Guerrero V; Herrero-Vanrell R
Drug Deliv Transl Res; 2024 Apr; ():. PubMed ID: 38602615
[TBL] [Abstract][Full Text] [Related]
6. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study.
Weinreb RN; Ong T; Scassellati Sforzolini B; Vittitow JL; Singh K; Kaufman PL;
Br J Ophthalmol; 2015 Jun; 99(6):738-45. PubMed ID: 25488946
[TBL] [Abstract][Full Text] [Related]
7. Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study.
Weinreb RN; Scassellati Sforzolini B; Vittitow J; Liebmann J
Ophthalmology; 2016 May; 123(5):965-73. PubMed ID: 26875002
[TBL] [Abstract][Full Text] [Related]
8. Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension.
Kaufman PL
Expert Opin Pharmacother; 2017 Mar; 18(4):433-444. PubMed ID: 28234563
[TBL] [Abstract][Full Text] [Related]
9. The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies.
Cavet ME; DeCory HH
J Ocul Pharmacol Ther; 2018; 34(1-2):52-60. PubMed ID: 28783422
[TBL] [Abstract][Full Text] [Related]
10. Regulation of Endothelin-1-Induced Trabecular Meshwork Cell Contractility by Latanoprostene Bunod.
Cavet ME; Vollmer TR; Harrington KL; VanDerMeid K; Richardson ME
Invest Ophthalmol Vis Sci; 2015 Jun; 56(6):4108-16. PubMed ID: 26114488
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study.
Medeiros FA; Martin KR; Peace J; Scassellati Sforzolini B; Vittitow JL; Weinreb RN
Am J Ophthalmol; 2016 Aug; 168():250-259. PubMed ID: 27210275
[TBL] [Abstract][Full Text] [Related]
12. Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study.
Kawase K; Vittitow JL; Weinreb RN; Araie M;
Adv Ther; 2016 Sep; 33(9):1612-27. PubMed ID: 27457469
[TBL] [Abstract][Full Text] [Related]
13. Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings.
Weinreb RN; Liebmann JM; Martin KR; Kaufman PL; Vittitow JL
J Glaucoma; 2018 Jan; 27(1):7-15. PubMed ID: 29194198
[TBL] [Abstract][Full Text] [Related]
14. eNOS, a pressure-dependent regulator of intraocular pressure.
Stamer WD; Lei Y; Boussommier-Calleja A; Overby DR; Ethier CR
Invest Ophthalmol Vis Sci; 2011 Dec; 52(13):9438-44. PubMed ID: 22039240
[TBL] [Abstract][Full Text] [Related]
15. Critical evaluation of latanoprostene bunod in the treatment of glaucoma.
Garcia GA; Ngai P; Mosaed S; Lin KY
Clin Ophthalmol; 2016; 10():2035-2050. PubMed ID: 27799730
[TBL] [Abstract][Full Text] [Related]
16. Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension.
Hoy SM
Drugs; 2018 May; 78(7):773-780. PubMed ID: 29761382
[TBL] [Abstract][Full Text] [Related]
17. The Interaction of Nepafenac and Prostaglandin Analogs in Primary Open-angle Glaucoma Patients.
Özyol P; Özyol E; Erdoğan BD
J Glaucoma; 2016 Mar; 25(3):e145-9. PubMed ID: 25493620
[TBL] [Abstract][Full Text] [Related]
18. Regulation of intraocular pressure by soluble and membrane guanylate cyclases and their role in glaucoma.
Buys ES; Potter LR; Pasquale LR; Ksander BR
Front Mol Neurosci; 2014; 7():38. PubMed ID: 24904270
[TBL] [Abstract][Full Text] [Related]
19. New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost.
Mehran NA; Sinha S; Razeghinejad R
Eye (Lond); 2020 Jan; 34(1):72-88. PubMed ID: 31695162
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
